Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice regarding partial amendment of the Articles of Incorporation
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus
Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 [Japanese GAAP]
2025 Fiscal Year End Business and Financial report
Strategic Development Progress Update for MDL-101: Clinical Readiness Advancement and Program Optimization
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss)
Notice Regarding the Variance between consolidated results and results of the previous year, non-consolidated results and results of the previous year
Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Financial Results for the Nine Months Ended September 30, 2025
Consolidated Financial Results for the Nine Months Ended September 30, 2025 [Japanese GAAP]
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss)
Notice Regarding Change of the Executive Officer
A Patent Grant for "Method for Treating Alzheimer’s Disease by Targeting the MAPT Gene"
Modalis Receives Japanese Patent for DUX4 Gene-Targeted Therapy for Facioscapulohumeral Muscular Dystrophy
Business Plans and Matters Related to High Growth Potential
Business and Financial report for Six Months Ended June 30, 2025
Consolidated Financial Results for the Six Months Ended June 30, 2025 [Japanese GAAP]
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss)
Modalis Therapeutics to Present Epigenome Editing Technology and Preclinical Data at the 6th Annual Genome Editing Therapeutics Summit